View the recording here: https://bit.ly/35KIwBb
Biopharmaceutical Industry recently increased adoption of Single-Use systems and components in manufacturing process operations. Drug manufacturers are responsible for the characterization of SU components and systems used for the production to ensure patient safety. SUS Suppliers are encouraged by BPOG and BPSA to provide comprehensive extractables data package to support drug manufacturer’s E&L assessments.
This webinar will give an overview of the E&L evaluation workflow and practical study approaches from both supplier and end-user perspective, in accordance with the latest industry’s standards and upcoming USP <665> requirements. Case studies will be presented on how the data from suppliers are used to mitigate risk associated to SU materials, highlighting the key role of collaboration between the supplier and the drug manufacturer.
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...MilliporeSigma
Register for the interactive, on-demand webinar now: https://bit.ly/USP665
Single-use plastic systems are being utilized more frequently especially for COVID-19 vaccine manufacturing. However, there are issues regarding standardization of quality information that limits implementation efficiencies. One of the challenges is the evaluation of leachables derived from a variety of different plastic components in a timely manner.
Since the USP <665> highlights a risk assessment approach with no typical pass/fail limit, approaches to decision-making based on the extractables data package will be reviewed. In addition, we will highlight legacy testing requirements which may not be necessary once USP <665> is implemented.
In this webinar, we will discuss:
- Regulatory expectations of extractables and leachables assessment today and tomorrow
- The right criteria that need to be assessed to select the type and quality of plastic materials for use in biopharmaceutical manufacturing
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...Merck Life Sciences
Register for the interactive, on-demand webinar now: https://bit.ly/USP665
Single-use plastic systems are being utilized more frequently especially for COVID-19 vaccine manufacturing. However, there are issues regarding standardization of quality information that limits implementation efficiencies. One of the challenges is the evaluation of leachables derived from a variety of different plastic components in a timely manner.
Since the USP <665> highlights a risk assessment approach with no typical pass/fail limit, approaches to decision-making based on the extractables data package will be reviewed. In addition, we will highlight legacy testing requirements which may not be necessary once USP <665> is implemented.
In this webinar, we will discuss:
- Regulatory expectations of extractables and leachables assessment today and tomorrow
- The right criteria that need to be assessed to select the type and quality of plastic materials for use in biopharmaceutical manufacturing
USP <665> draft standard : A rational risk-based approach to characterization...MilliporeSigma
This webinar will cover risk-based characterization of filters and single-use systems used in biopharmaceutical manufacturing according to USP <665>.
Novel innovative biomanufacturing systems such as single-use assemblies often comprise of polymeric materials. There is a lack of standards for characterization of these polymeric systems. USP <665> draft standard is the first standard in development addressing this topic. This chapter recommends risk assessment with respect to patient safety, risk level assignment and risk level appropriate characterization of components.
In this webinar we will discuss:
● Risk assessment to assign a risk level
● Risk level based testing
● Our approach for compliance
● Emprove™ Dossiers for Filters and Single-use systems
USP <665> draft standard : A rational risk-based approach to characterization...Merck Life Sciences
This webinar will cover risk-based characterization of filters and single-use systems used in biopharmaceutical manufacturing according to USP <665>.
Novel innovative biomanufacturing systems such as single-use assemblies often comprise of polymeric materials. There is a lack of standards for characterization of these polymeric systems. USP <665> draft standard is the first standard in development addressing this topic. This chapter recommends risk assessment with respect to patient safety, risk level assignment and risk level appropriate characterization of components.
In this webinar we will discuss:
● Risk assessment to assign a risk level
● Risk level based testing
● Our approach for compliance
● Emprove™ Dossiers for Filters and Single-use systems
Considerations to Extractables and Leachables Testing SGS
How to organize Extractables Assessments? FDA continues to issue Warning Letters to companies that fail to properly complete Design Verification, Design Validation, and Process Validation, and recently to include failures of manufacturers in Risk Management. The evaluation of extractables and leachables has become an increasingly important aspect in the Quality by Design (QbD) initiative of the FDA in the area of drug product design, including materials used in the drug product production process and container and closure systems used for product packaging. This presentation provides general approaches and practical aspects in E&L testing.
Challenges using Multiple Single-use Systems: Functionality versus Extractabl...Merck Life Sciences
As single-use technologies continue to expand in pharmaceutical manufacturing processes, the risk assessment for extractables and leachables becomes increasingly complex. Join this webinar to obtain guidance on how to perform risk evaluation on a process with multiple single-use components.
A Single-Use System (SUS) is typically designed for a specific process step. In many cases, single-use components are chosen based on their functionality. The challenge arises when there are multiple processing steps-- as the different applications and product matrices are evaluated, the complexity of the risk assessment increases. Complexity includes component evaluation, process conditions, and model solvents streams which ultimately relates to the patient safety risk.
This webinar will evaluate the different single-use components with respect to compatibility and extractables and leachables. A case study will be used to demonstrate the complexity and potential concerns when performing a risk evaluation on the manufacturing process.
In this webinar, you will learn:
- Risk assessment of extractables
- Single-use component evaluation
- Complexity when evaluating multiple assemblies
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...MilliporeSigma
Register for the interactive, on-demand webinar now: https://bit.ly/USP665
Single-use plastic systems are being utilized more frequently especially for COVID-19 vaccine manufacturing. However, there are issues regarding standardization of quality information that limits implementation efficiencies. One of the challenges is the evaluation of leachables derived from a variety of different plastic components in a timely manner.
Since the USP <665> highlights a risk assessment approach with no typical pass/fail limit, approaches to decision-making based on the extractables data package will be reviewed. In addition, we will highlight legacy testing requirements which may not be necessary once USP <665> is implemented.
In this webinar, we will discuss:
- Regulatory expectations of extractables and leachables assessment today and tomorrow
- The right criteria that need to be assessed to select the type and quality of plastic materials for use in biopharmaceutical manufacturing
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...Merck Life Sciences
Register for the interactive, on-demand webinar now: https://bit.ly/USP665
Single-use plastic systems are being utilized more frequently especially for COVID-19 vaccine manufacturing. However, there are issues regarding standardization of quality information that limits implementation efficiencies. One of the challenges is the evaluation of leachables derived from a variety of different plastic components in a timely manner.
Since the USP <665> highlights a risk assessment approach with no typical pass/fail limit, approaches to decision-making based on the extractables data package will be reviewed. In addition, we will highlight legacy testing requirements which may not be necessary once USP <665> is implemented.
In this webinar, we will discuss:
- Regulatory expectations of extractables and leachables assessment today and tomorrow
- The right criteria that need to be assessed to select the type and quality of plastic materials for use in biopharmaceutical manufacturing
USP <665> draft standard : A rational risk-based approach to characterization...MilliporeSigma
This webinar will cover risk-based characterization of filters and single-use systems used in biopharmaceutical manufacturing according to USP <665>.
Novel innovative biomanufacturing systems such as single-use assemblies often comprise of polymeric materials. There is a lack of standards for characterization of these polymeric systems. USP <665> draft standard is the first standard in development addressing this topic. This chapter recommends risk assessment with respect to patient safety, risk level assignment and risk level appropriate characterization of components.
In this webinar we will discuss:
● Risk assessment to assign a risk level
● Risk level based testing
● Our approach for compliance
● Emprove™ Dossiers for Filters and Single-use systems
USP <665> draft standard : A rational risk-based approach to characterization...Merck Life Sciences
This webinar will cover risk-based characterization of filters and single-use systems used in biopharmaceutical manufacturing according to USP <665>.
Novel innovative biomanufacturing systems such as single-use assemblies often comprise of polymeric materials. There is a lack of standards for characterization of these polymeric systems. USP <665> draft standard is the first standard in development addressing this topic. This chapter recommends risk assessment with respect to patient safety, risk level assignment and risk level appropriate characterization of components.
In this webinar we will discuss:
● Risk assessment to assign a risk level
● Risk level based testing
● Our approach for compliance
● Emprove™ Dossiers for Filters and Single-use systems
Considerations to Extractables and Leachables Testing SGS
How to organize Extractables Assessments? FDA continues to issue Warning Letters to companies that fail to properly complete Design Verification, Design Validation, and Process Validation, and recently to include failures of manufacturers in Risk Management. The evaluation of extractables and leachables has become an increasingly important aspect in the Quality by Design (QbD) initiative of the FDA in the area of drug product design, including materials used in the drug product production process and container and closure systems used for product packaging. This presentation provides general approaches and practical aspects in E&L testing.
Challenges using Multiple Single-use Systems: Functionality versus Extractabl...Merck Life Sciences
As single-use technologies continue to expand in pharmaceutical manufacturing processes, the risk assessment for extractables and leachables becomes increasingly complex. Join this webinar to obtain guidance on how to perform risk evaluation on a process with multiple single-use components.
A Single-Use System (SUS) is typically designed for a specific process step. In many cases, single-use components are chosen based on their functionality. The challenge arises when there are multiple processing steps-- as the different applications and product matrices are evaluated, the complexity of the risk assessment increases. Complexity includes component evaluation, process conditions, and model solvents streams which ultimately relates to the patient safety risk.
This webinar will evaluate the different single-use components with respect to compatibility and extractables and leachables. A case study will be used to demonstrate the complexity and potential concerns when performing a risk evaluation on the manufacturing process.
In this webinar, you will learn:
- Risk assessment of extractables
- Single-use component evaluation
- Complexity when evaluating multiple assemblies
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...Merck Life Sciences
What are the major drivers for the new Annex 1? Join us to know more about implications for Filters & Single Use.
In this webinar, you will learn:
• Closed Processing and Single Use Technology implementation
• Points to consider using Single Use Technology
• Sterile Filtration
The Annex 1 “Manufacture of sterile medicinal products” of the EU GMP Guide is currently being revised. A first draft of the revised version was published in 2017 and released for public comment. The second draft as of February 2020 was open for targeted consultation via stakeholder from selected industry organisations. The current Annex 1 draft emphasises Contamination Control Strategy (CCS) multiple times and as a key consideration.
In the last year or so the FDA and the EMA have issued new guidance/ draft guidance on "Process Validation".These align process validation activities with a product lifecycle concept and the International Conference on Harmonisation (ICH) guidances for industry, Q8(R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The earlier guidelines were developed before the elaboration of the new ICH guidelines.With these new guidelines, additional opportunities are available to verify the control of the process by alternative means to the manufacture of traditional process validation batches. The main objective of process validation remains that a process design yields a product meeting its pre-defined quality criteria. ICH Q8, Q9 and Q10 provide a structured way to define product critical quality attributes, design space, the manufacturing process and the control strategy. ICH Q8 refers to an ‘enhanced’ approach to pharmaceutical development which includes an alternative to the traditional process validation.
Continuous process verification [see definition in ICH Q8(R2) glossary] can be utilised in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.
There is now a new paradigm in process validation. This presentation has been prepared from material available from FDA , EMA and ICH for beginners to have an overview of the new paradigm.
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3kk0Qs1
In this webinar, you will learn:
- About the GMP Annex 1 draft regulatory overview
- How to incorporate the integrity testing & PUPSIT in the filtration systems validation
- How to design a bacterial retention test in terms of organism selection and single vs multiple use validation
Detailed description:
In this webinar we will discuss the implications of the EU GMP Annex 1 draft on the filtration of medicinal products and how this impacts the validation studies.
Bacterial Retention Testing is a critical part of the manufacturing validation process and is required by all regulatory bodies worldwide. Using case studies, our experts will explain how the Annex 1 draft is incorporated into the filtration systems validation exercise, specifically for integrity testing & PUPSIT (Pre-Use Post Sterilization Integrity Testing), the selection and justification of the appropriate test organism, and validation implications of single versus multiple use.
FDA’s emphasis on quality by design began with the recognition that increased testing does not improve product quality (this has long been recognized in other industries).In order for quality to increase, it must be built into the product. To do this requires understanding how formulation and manufacturing process variables influence product quality.Quality by Design (QbD) is a systematic approach to pharmaceutical development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management.
This presentation - Part III in the series- deals with the concepts of critical material attributes, critical process parameters , their linage to the the critical Quality attributes of the Product and Quality Risk Management and its pivotal role in the QbD process.Concepts of control strategy are also discussed briefly.
This presentation was compiled from material freely available from FDA , ICH , EMEA and other free resources on the world wide web.
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationMilliporeSigma
Watch the presentation of this webinar here: https://bit.ly/3kk0Qs1
In this webinar, you will learn:
- About the GMP Annex 1 draft regulatory overview
- How to incorporate the integrity testing & PUPSIT in the filtration systems validation
- How to design a bacterial retention test in terms of organism selection and single vs multiple use validation
Detailed description:
In this webinar we will discuss the implications of the EU GMP Annex 1 draft on the filtration of medicinal products and how this impacts the validation studies.
Bacterial Retention Testing is a critical part of the manufacturing validation process and is required by all regulatory bodies worldwide. Using case studies, our experts will explain how the Annex 1 draft is incorporated into the filtration systems validation exercise, specifically for integrity testing & PUPSIT (Pre-Use Post Sterilization Integrity Testing), the selection and justification of the appropriate test organism, and validation implications of single versus multiple use.
Addressing Downstream Challenges with Complex InjectablesMerck Life Sciences
The complex injectable market is gaining traction in the injectable therapies, however manufacturing of it is critical. In this webinar, lets brainstorm on the downstream criticalities of these molecules and how to handle the same.
Cell Culture Media Filtration – Filter Selection and SizingMilliporeSigma
The purpose of this application note is to provide estimated filtration areas for different sterilizing-grade filters with a panel of media used for Chinese Hamster Ovary (CHO) cell culture processes.
This presentation gives an idea about extractable and leachables, Analytical techniques used for conducting studies. importance of conducting E&L studies.
Learn how Quality By Design (QBD) principles can be applied to understand the critical processing and feed parameters affecting virus retention, allowing the development of a streamlined validation approach and robust process control strategy for virus clearance via filtration.
In this webinar, you will learn:
•How to simplify validation study design
•Identify critical process and feed parameters affecting virus retention
•How to compile a robust regulatory filing package
Abstract:
ICH Q8 defines Quality by Design (QbD) as “…a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on quality risk management.” Within the context of virus clearance for bioprocesses, QbD principles can be applied to understand the critical processing and feed parameters affecting virus retention, guiding the development of a streamlined validation approach and robust process control strategy for virus clearance unit operations. We will explore how QbD principles can be applied to downstream virus filtration of mAbs and recombinants, the application of these principles within the framework of the Viresolve® Pro Device (parvovirus retentive filter), the benefits through simplifying the validation strategy and increasing the robustness of your regulatory filing package.
For an unparalleled experience throughout the life cycle of your therapy, BioReliance® world-class biosafety solutions offer a full range of GMP cell banking services, cell line and virus bank characterization, viral clearance and lot release testing. Merck’s complete biosafety testing solutions, paired with our long-standing reputation for quality and expertise, will give you the mission-critical capabilities to bring safe, life-changing medicines to market.
Challenges using Multiple Single-use Systems: Functionality versus Extractabl...MilliporeSigma
As single-use technologies continue to expand in pharmaceutical manufacturing processes, the risk assessment for extractables and leachables becomes increasingly complex. Join this webinar to obtain guidance on how to perform risk evaluation on a process with multiple single-use components.
A Single-Use System (SUS) is typically designed for a specific process step. In many cases, single-use components are chosen based on their functionality. The challenge arises when there are multiple processing steps-- as the different applications and product matrices are evaluated, the complexity of the risk assessment increases. Complexity includes component evaluation, process conditions, and model solvents streams which ultimately relates to the patient safety risk.
This webinar will evaluate the different single-use components with respect to compatibility and extractables and leachables. A case study will be used to demonstrate the complexity and potential concerns when performing a risk evaluation on the manufacturing process.
In this webinar, you will learn:
- Risk assessment of extractables
- Single-use component evaluation
- Complexity when evaluating multiple assemblies
Extractables profiles for chromatography resins - adapted approach of upcomin...MilliporeSigma
Watch the webinar here: https://bit.ly/36JaZpx
In biopharmaceutical industry there is a trend towards comprehensive risk assessments of drug manufacturing processes. Extractables studies for chromatography resins based on the adapted requirements of the upcoming USP <665> support risk evaluation for your specific chromatography steps.
In this webinar, you will learn about:
- Study design for extractables profiles of chromatography resins
- The new category Emprove® Chromatography
- Communication of extractables data as part of Emprove® Dossiers
Description:
Detailed information on any component or material in contact with the drug substance/ product is required to conduct a compreshensive risk assessment of a biopharmaceutical manufacturing process. No explicit guidelines providing required testing procedures for chromatography steps are in place yet. In the upcoming USP <665> chapter chromatography steps are in focus as well as any other plastic or polymeric component and can as such assessed as to the described criteria. To support our chromatography resin users an adapted extractables study approach was developed. The webinar will demonstrate our study design and the communication of the extractables profiles within our Emprove® Program.
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...Merck Life Sciences
What are the major drivers for the new Annex 1? Join us to know more about implications for Filters & Single Use.
In this webinar, you will learn:
• Closed Processing and Single Use Technology implementation
• Points to consider using Single Use Technology
• Sterile Filtration
The Annex 1 “Manufacture of sterile medicinal products” of the EU GMP Guide is currently being revised. A first draft of the revised version was published in 2017 and released for public comment. The second draft as of February 2020 was open for targeted consultation via stakeholder from selected industry organisations. The current Annex 1 draft emphasises Contamination Control Strategy (CCS) multiple times and as a key consideration.
In the last year or so the FDA and the EMA have issued new guidance/ draft guidance on "Process Validation".These align process validation activities with a product lifecycle concept and the International Conference on Harmonisation (ICH) guidances for industry, Q8(R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The earlier guidelines were developed before the elaboration of the new ICH guidelines.With these new guidelines, additional opportunities are available to verify the control of the process by alternative means to the manufacture of traditional process validation batches. The main objective of process validation remains that a process design yields a product meeting its pre-defined quality criteria. ICH Q8, Q9 and Q10 provide a structured way to define product critical quality attributes, design space, the manufacturing process and the control strategy. ICH Q8 refers to an ‘enhanced’ approach to pharmaceutical development which includes an alternative to the traditional process validation.
Continuous process verification [see definition in ICH Q8(R2) glossary] can be utilised in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.
There is now a new paradigm in process validation. This presentation has been prepared from material available from FDA , EMA and ICH for beginners to have an overview of the new paradigm.
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3kk0Qs1
In this webinar, you will learn:
- About the GMP Annex 1 draft regulatory overview
- How to incorporate the integrity testing & PUPSIT in the filtration systems validation
- How to design a bacterial retention test in terms of organism selection and single vs multiple use validation
Detailed description:
In this webinar we will discuss the implications of the EU GMP Annex 1 draft on the filtration of medicinal products and how this impacts the validation studies.
Bacterial Retention Testing is a critical part of the manufacturing validation process and is required by all regulatory bodies worldwide. Using case studies, our experts will explain how the Annex 1 draft is incorporated into the filtration systems validation exercise, specifically for integrity testing & PUPSIT (Pre-Use Post Sterilization Integrity Testing), the selection and justification of the appropriate test organism, and validation implications of single versus multiple use.
FDA’s emphasis on quality by design began with the recognition that increased testing does not improve product quality (this has long been recognized in other industries).In order for quality to increase, it must be built into the product. To do this requires understanding how formulation and manufacturing process variables influence product quality.Quality by Design (QbD) is a systematic approach to pharmaceutical development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management.
This presentation - Part III in the series- deals with the concepts of critical material attributes, critical process parameters , their linage to the the critical Quality attributes of the Product and Quality Risk Management and its pivotal role in the QbD process.Concepts of control strategy are also discussed briefly.
This presentation was compiled from material freely available from FDA , ICH , EMEA and other free resources on the world wide web.
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationMilliporeSigma
Watch the presentation of this webinar here: https://bit.ly/3kk0Qs1
In this webinar, you will learn:
- About the GMP Annex 1 draft regulatory overview
- How to incorporate the integrity testing & PUPSIT in the filtration systems validation
- How to design a bacterial retention test in terms of organism selection and single vs multiple use validation
Detailed description:
In this webinar we will discuss the implications of the EU GMP Annex 1 draft on the filtration of medicinal products and how this impacts the validation studies.
Bacterial Retention Testing is a critical part of the manufacturing validation process and is required by all regulatory bodies worldwide. Using case studies, our experts will explain how the Annex 1 draft is incorporated into the filtration systems validation exercise, specifically for integrity testing & PUPSIT (Pre-Use Post Sterilization Integrity Testing), the selection and justification of the appropriate test organism, and validation implications of single versus multiple use.
Addressing Downstream Challenges with Complex InjectablesMerck Life Sciences
The complex injectable market is gaining traction in the injectable therapies, however manufacturing of it is critical. In this webinar, lets brainstorm on the downstream criticalities of these molecules and how to handle the same.
Cell Culture Media Filtration – Filter Selection and SizingMilliporeSigma
The purpose of this application note is to provide estimated filtration areas for different sterilizing-grade filters with a panel of media used for Chinese Hamster Ovary (CHO) cell culture processes.
This presentation gives an idea about extractable and leachables, Analytical techniques used for conducting studies. importance of conducting E&L studies.
Learn how Quality By Design (QBD) principles can be applied to understand the critical processing and feed parameters affecting virus retention, allowing the development of a streamlined validation approach and robust process control strategy for virus clearance via filtration.
In this webinar, you will learn:
•How to simplify validation study design
•Identify critical process and feed parameters affecting virus retention
•How to compile a robust regulatory filing package
Abstract:
ICH Q8 defines Quality by Design (QbD) as “…a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on quality risk management.” Within the context of virus clearance for bioprocesses, QbD principles can be applied to understand the critical processing and feed parameters affecting virus retention, guiding the development of a streamlined validation approach and robust process control strategy for virus clearance unit operations. We will explore how QbD principles can be applied to downstream virus filtration of mAbs and recombinants, the application of these principles within the framework of the Viresolve® Pro Device (parvovirus retentive filter), the benefits through simplifying the validation strategy and increasing the robustness of your regulatory filing package.
For an unparalleled experience throughout the life cycle of your therapy, BioReliance® world-class biosafety solutions offer a full range of GMP cell banking services, cell line and virus bank characterization, viral clearance and lot release testing. Merck’s complete biosafety testing solutions, paired with our long-standing reputation for quality and expertise, will give you the mission-critical capabilities to bring safe, life-changing medicines to market.
Challenges using Multiple Single-use Systems: Functionality versus Extractabl...MilliporeSigma
As single-use technologies continue to expand in pharmaceutical manufacturing processes, the risk assessment for extractables and leachables becomes increasingly complex. Join this webinar to obtain guidance on how to perform risk evaluation on a process with multiple single-use components.
A Single-Use System (SUS) is typically designed for a specific process step. In many cases, single-use components are chosen based on their functionality. The challenge arises when there are multiple processing steps-- as the different applications and product matrices are evaluated, the complexity of the risk assessment increases. Complexity includes component evaluation, process conditions, and model solvents streams which ultimately relates to the patient safety risk.
This webinar will evaluate the different single-use components with respect to compatibility and extractables and leachables. A case study will be used to demonstrate the complexity and potential concerns when performing a risk evaluation on the manufacturing process.
In this webinar, you will learn:
- Risk assessment of extractables
- Single-use component evaluation
- Complexity when evaluating multiple assemblies
Extractables profiles for chromatography resins - adapted approach of upcomin...MilliporeSigma
Watch the webinar here: https://bit.ly/36JaZpx
In biopharmaceutical industry there is a trend towards comprehensive risk assessments of drug manufacturing processes. Extractables studies for chromatography resins based on the adapted requirements of the upcoming USP <665> support risk evaluation for your specific chromatography steps.
In this webinar, you will learn about:
- Study design for extractables profiles of chromatography resins
- The new category Emprove® Chromatography
- Communication of extractables data as part of Emprove® Dossiers
Description:
Detailed information on any component or material in contact with the drug substance/ product is required to conduct a compreshensive risk assessment of a biopharmaceutical manufacturing process. No explicit guidelines providing required testing procedures for chromatography steps are in place yet. In the upcoming USP <665> chapter chromatography steps are in focus as well as any other plastic or polymeric component and can as such assessed as to the described criteria. To support our chromatography resin users an adapted extractables study approach was developed. The webinar will demonstrate our study design and the communication of the extractables profiles within our Emprove® Program.
Extractables profiles for chromatography resins - adapted approach of upcomin...Merck Life Sciences
Watch the webinar here: https://bit.ly/36JaZpx
In biopharmaceutical industry there is a trend towards comprehensive risk assessments of drug manufacturing processes. Extractables studies for chromatography resins based on the adapted requirements of the upcoming USP <665> support risk evaluation for your specific chromatography steps.
In this webinar, you will learn about:
- Study design for extractables profiles of chromatography resins
- The new category Emprove® Chromatography
- Communication of extractables data as part of Emprove® Dossiers
Description:
Detailed information on any component or material in contact with the drug substance/ product is required to conduct a compreshensive risk assessment of a biopharmaceutical manufacturing process. No explicit guidelines providing required testing procedures for chromatography steps are in place yet. In the upcoming USP <665> chapter chromatography steps are in focus as well as any other plastic or polymeric component and can as such assessed as to the described criteria. To support our chromatography resin users an adapted extractables study approach was developed. The webinar will demonstrate our study design and the communication of the extractables profiles within our Emprove® Program.
The Role of BPOG Extractables Data in the Effective Adoption of Single-Use Sy...Merck Life Sciences
The successful adoption of single-use technologies in a biopharmaceutical process largely relies on confidently selecting the right components for use in the fluid path of a product, within a specific process. An important step in choosing such components requires generating an extractables profile, which can be done by carefully selecting the solvent streams and extraction conditions to model the product and process steps complemented with the right analytical strategy.
In this webinar, you will learn:
● An approach to adopt the BioPhorum Operations Group (BPOG) extractables protocol as a baseline testing strategy.
● How to apply extractables data to a specific process followed by a systematic, risk-based safety assessment approach used for comparing known safety concern thresholds.
● The important stages in the risk assessment process as demonstrated by case studies from typical drug manufacturing processes where single-use components were used.
Aseptic Process Sampling to address Risk of Contamination & Containment in co...Merck Life Sciences
In this webinar, you will learn:
- The challenges tied to contamination control within a biopharmaceutical environment.
- What closed processing is, and how sampling solutions are an integral component towards that end.
- Advantages of sterile sampling from both a technical and economical viewpoint; with the review of a technical study confirming contamination risk reduction and total cost of ownership.
- Recommendations and requirements stated by these major regulatory authorities around the monitoring of the manufacturing process with the execution of sampling.
Detailed description:
Biopharmaceutical manufacturers are required to ensure drug product quality attributes for patient safety. Strong contamination control strategies should be considered early in process design, and have direct influence on the production environment and equipment selection.
Sampling at each step is a critical component in maintaining a contamination control strategy. Regulators are critical in the sampling process, as it predicts the state of the product or process, and needs to be Representative. A case study will be presented that demonstrates a closed, robust sampling solution capable of maintaining a sterile flow path when challenged with Brevundimonas diminuta. The sampling option you select can help support your goal in achieving a closed process, improving your risk mitigation strategy and product safety.
Aseptic Process Sampling to address Risk of Contamination & Containment in co...MilliporeSigma
Watch this webinar here: bit.ly/asepticwebinar2020
In this webinar, you will learn:
- The challenges tied to contamination control within a biopharmaceutical environment.
- What closed processing is, and how sampling solutions are an integral component towards that end.
- Advantages of sterile sampling from both a technical and economical viewpoint; with the review of a technical study confirming contamination risk reduction and total cost of ownership.
- Recommendations and requirements stated by these major regulatory authorities around the monitoring of the manufacturing process with the execution of sampling.
Detailed description:
Biopharmaceutical manufacturers are required to ensure drug product quality attributes for patient safety. Strong contamination control strategies should be considered early in process design, and have direct influence on the production environment and equipment selection.
Sampling at each step is a critical component in maintaining a contamination control strategy. Regulators are critical in the sampling process, as it predicts the state of the product or process, and needs to be Representative. A case study will be presented that demonstrates a closed, robust sampling solution capable of maintaining a sterile flow path when challenged with Brevundimonas diminuta. The sampling option you select can help support your goal in achieving a closed process, improving your risk mitigation strategy and product safety.
The students will get a glimpse of industrial bioprocess from this presentation. Additionally, it will help students make the transition from academia to industry.
Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving R...MilliporeSigma
This webinar will discuss appropriate quality attributes for different raw material uses, present strategies to support identification, selection and risk assessment of raw materials, and highlight the importance of regulatory documentation.
Recent and continuing regulatory improvements require drug manufacturers to assess and mitigate risk throughout their entire processes. This includes raw materials used at every stage of manufacturing and clinical phases. Current regulatory guidelines and industry standards clearly define quality requirements for raw materials that are incorporated into, or used close to, final drug product, for example active ingredients and excipients. However, no such clear standards are defined for chemicals used earlier in the process, such as in upstream bioprocessing, early chemical synthesis stages, or clean-in-place. The absence of such standards presents a challenge to efficiently and effectively source raw materials with appropriate supply chain transparency and control, accompanied by the necessary supporting documentation.
In this webinar, you will learn:
• Strategies to support identification, selection, and risk assessment of raw materials throughout the manufacturing process
• Appropriate quality attributes for different raw material uses
• The importance of quality and regulatory documentation provided by the supplier
Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving R...Merck Life Sciences
This webinar will discuss appropriate quality attributes for different raw material uses, present strategies to support identification, selection and risk assessment of raw materials, and highlight the importance of regulatory documentation.
Recent and continuing regulatory improvements require drug manufacturers to assess and mitigate risk throughout their entire processes. This includes raw materials used at every stage of manufacturing and clinical phases. Current regulatory guidelines and industry standards clearly define quality requirements for raw materials that are incorporated into, or used close to, final drug product, for example active ingredients and excipients. However, no such clear standards are defined for chemicals used earlier in the process, such as in upstream bioprocessing, early chemical synthesis stages, or clean-in-place. The absence of such standards presents a challenge to efficiently and effectively source raw materials with appropriate supply chain transparency and control, accompanied by the necessary supporting documentation.
In this webinar, you will learn:
• Strategies to support identification, selection, and risk assessment of raw materials throughout the manufacturing process
• Appropriate quality attributes for different raw material uses
• The importance of quality and regulatory documentation provided by the supplier
Quality by design for Pharmaceutical Industries: An introductionCovello Luca
In this presentation, I have attempted to provide a quick introduction into the main concepts behind Pharmaceutical Quality by Design, an approach that aims to ensure the quality of medicines by employing statistical, analytical and risk-management methodology in the design, development and manufacturing of drugs.
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...MilliporeSigma
What are the major drivers for the new Annex 1? Join us to know more about implications for Filters & Single Use.
In this webinar, you will learn:
• Closed Processing and Single Use Technology implementation
• Points to consider using Single Use Technology
• Sterile Filtration
The Annex 1 “Manufacture of sterile medicinal products” of the EU GMP Guide is currently being revised. A first draft of the revised version was published in 2017 and released for public comment. The second draft as of February 2020 was open for targeted consultation via stakeholder from selected industry organisations. The current Annex 1 draft emphasises Contamination Control Strategy (CCS) multiple times and as a key consideration.
pilot plant is a small system which is operated to find out about the behavior of a process before using it on a large industrial scale. so, this presentation tries to illustrate its objective and significance to understand the methodologies of various pharmaceutical dosage forms.
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...Merck Life Sciences
Protein viscosity is a major challenge in preparing highly concentrated protein formulations suitable for subcutaneous injection. Recently, the Viscosity Reduction Platform (VRP) was introduced and its technical key features and benefits for formulations were discussed. However, highly viscous solutions do not only pose a challenge when administering a drug to a patient, they can also impose technical limitations in the manufacturing process.
This white paper evaluates the effect of the excipients in the Viscosity Reduction Platform on ultrafiltration processes used to produce a highly concentrated formulation of a monoclonal antibody (mAb). Two filtration methods are demonstrated in this work.
Find more information about the Viscosity Reduction Platform on our website: https://www.sigmaaldrich.com/products/pharma-and-biopharma-manufacturing/formulation/viscosity-reduction-platform
Use of Excipients in Downstream Processing to Improve Protein PurificationMerck Life Sciences
Excipients are used to improve the stability of protein-based therapeutics by protecting the protein against a range of stress conditions such as temperature changes, pH changes, or agitation. Similar stresses are applied to proteins during downstream purification. Shifts in pH during Protein A chromatography, subsequent incubations at low pH for virus inactivation, and changes in conductivity in ion exchange chromatography can lead to aggregation, fragmentation, or other chemical modifications of the therapeutic protein. Given the potential impact on the protein’s structural integrity, there is a need for approaches to reduce the risk presented by the conditions during downstream processing. For example, integration of a solution to prevent aggregation of proteins would be a more efficient strategy than implementing steps to remove multimeric forms.
This white paper highlights the results from a recent paper by Stange et. al., in which protein stabilizing excipients such as polyols, sugars, and polyethylene glycol (PEG4000) were used as buffer system additives. Effect of the excipients on elution patterns, stabilization of the monomer antibody, host-cell protein removal, virus inactivation rates and binding capacity of cation exchange chromatography were explored.
Exploring the protein stabilizing capability of surfactants against agitation...Merck Life Sciences
Agitation of therapeutic protein solutions during manufacturing, shipping and handling is one of the major initiators for protein aggregation and particle formation during the life history of a protein drug. Adsorption of protein molecules to liquid-air interfaces leads to the formation of highly concentrated protein surface films. The rupture of these protein films due to various mechanical processes can then result in the appearance of protein aggregates and particles in the bulk solution phase.
One technique to stabilize proteins against stress induced by liquid-air interfaces is the use of non-ionic surfactants. About 91% of antibody formulations commercially available in 2021 contained a surfactant. Polysorbate 20 and 80, composed of a hydrophilic polyoxyethylene sorbitan and hydrophobic fatty acid esters, made up the largest part being employed in 87% of said formulations.
Despite their frequent use in parenteral drug products, concerns have been raised for decades about the application of polysorbates as surfactants in biopharmaceutical formulations. Autoxidation of polysorbate, caused by residual peroxides in polysorbates, can damage the proteins and can further drive the oxidative degradation of polysorbate. Chemical and enzymatic hydrolysis of polysorbate may lead to the formation of free fatty acid particles, which may become visible; and both mechanisms eventually lead to the reduction in polysorbate concentration. Therefore, the purpose of the current study was to compare various molecules for their capabilities to reduced agitation-induced protein aggregation and particle formation; and furthermore, investigate their underlying protein stabilizing mechanisms.
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...Merck Life Sciences
Protein viscosity is one of the major obstacles in preparing highly concentrated protein formulations suitable for subcutaneous injection.
This whitepaper examines how combining an amino acid with a second viscosity-reducing excipient circumvents adverse effects on protein stability and improves viscosity-reducing capacity.
To find more information about the Viscosity Reduction Platform, please visit our website: https://sigmaaldrich.com/products/pharma-and-biopharma-manufacturing/formulation/viscosity-reduction-platform
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Merck Life Sciences
Watch the presentation of this webinar: https://bit.ly/3Pjpjvr
Highlights of this webinar:
- Surface plasmon resonance as a powerful tool for biologic characterization including mAbs and ADCs.
- SPR allows rapid binding analysis in real time without using labels for SARS-CoV-2 receptor binding domain mutations.
- Kinetic data is indicative of possible neutralizing activity allowed assessment of neutralizing ability of therapeutic monoclonal antibodies.
- The application can provide preliminarily efficacy information and facilitated mAbs/ACDs candidate selection process
Detailed description:
Characterization of therapeutic monoclonal antibodies (mAbs) or Antibody drug conjugates (ADCs) is challenging due to their ability to bind to a variety of proteins via their Fc and Fab domains, giving rise to diverse biological functions associated with each domain. The Fc domain of mAbs interacts with Fc receptors with varying affinities, which can influence biological processes such as Complement-dependent cytotoxicity (CDC) and Antibody-dependent cellular cytotoxicity (ADCC), transcytosis, phagocytosis, and/or serum half-life.
An important characteristic of an antibody is its Fc effector function. Antibodies can be engineered to obtain desired binding of the Fc region to Fc receptors expressed on effector cells. Hence, it is crucial to evaluate the binding interaction of mAbs/ADC with Fc receptors in the early phase of drug development to understand the potential biological activity of the product in vivo.
Surface Plasmon Resonance (SPR) is a powerful technique to establish binding kinetics in real-time, label free, and high sensitivity with low sample consumption. Along with target antigen binding, it is crucial to evaluate the binding interaction of antibodies and ADCs with Fc receptors. Our SPR case studies investigated the impact on binding kinetics of ADCs with different linkers and the binding interactions of SARS-CoV-2 spike protein variants and evaluated the neutralizing ability of therapeutic mAbs. SPR characterisation can be facilitated in all stages of the product life cycle to ensure the quality and safety of mAbs and ADCs.
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...Merck Life Sciences
Regulatory expectation does require patient safety evaluations with supporting data for manufacturing components that directly come into contact with drug manufacturing process streams. Readily available extractables data can help manufacturers using singleuse technology to accelerate product qualifications, risk assessments and process optimization
This white paper guides you on how to save time and resources with supplier-provided single-use system extractables data and gives you an overview about the overall strategy for Extractables & Leachables. At the end you will find a case study.
Find more information about filters and single-use components on our website: https://www.sigmaaldrich.com/DE/en/services/product-services/emprove-program/emprove-filter-and-single-use-component-portfolio
Watch the recording of this presentation here: https://bit.ly/3zTOpe4
Detailed description:
SARS-CoV-2 showed us that technology supports us during our inspection activity even if on-site visits are not possible. Travel restrictions of various kinds will remain a risk in the future. The use of new technologies has shown that inspections and audits can be carried out despite these restrictions. We will focus on what possibilities the new technologies offer and take a look at the future of inspections and audits.
In this webinar, you will learn:
• Regulatory overview of remote audits
• The technologies needed to support the audit process
• What types of inspections are possible with the use of these technologies
• How audits may look in the future
Presented by:
Daniel Buescher, Product Manager - Digital Solutions
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Merck Life Sciences
Watch the recording of this presentation here: https://bit.ly/3SqOsoP
Novel therapies, including cell and gene therapies, continue to be central to innovation in healthcare and represent the fastest growing area of therapeutic medicine. As a consequence, the number of gene therapies undergoing clinical trials has increased significantly in the last five years.
Manufacturing processes for these novel therapeutics are very complex with a high risk of contamination. Regulatory agencies world-wide have responded by issuing guidance to outline their expectations for development and manufacture of cell and gene therapies. Currently, regulatory guidance is not harmonized globally and can often lead to confusion within industry and increased risk of non-compliance.
In this webinar, we'll answer:
• Which regulatory guidelines do you need to comply for your INDs?
• When do you start implementing GMPs and validated assays?
• How do you get your QC testing strategy ‘right the first time’?
• How do you ensure testing is not your rate limiting step for the IND submission?
Presented by:
Manjula Aysola, Senior Regulatory Consultant
Dr. Alison Armstrong, Sr. Director, Technical and Scientific Solutions
Identity testing by NGS as a means of risk mitigation for viral gene therapiesMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3RijkHC
Detailed description:
Imagine you’ve just completed a manufacturing run for your viral vector. Identity testing is performed to confirm the vector sequence. But when the results come back the data reveals unexpected sequence variants! With an appropriate risk mitigation testing strategy, this situation can be prevented.
The situation described above is not hypothetical, and happens more that you think, costing valuable time and resources.
Investigatory testing has shown that sequence variants present in starting materials (e.g. plasmids) are likely to make their way to the final product. Adequate identification of low-level variants with an appropriately sensitive method is critical in ensuring the quality of the final product. A risk-based testing strategy, in the context of identity, for viral vector manufacturing will be presented, focusing on key testing points. NGS assays for identity and variant detection will be highlighted due to their extremely sensitive nature compared to traditional approaches.
In this webinar, we'll explore:
• Regulatory requirements for identity testing
• NGS applications for identity testing as compared to traditional methods
• A case study on the impact of not establishing a proper risk-based testing strategy
Presented by: Bradley Hasson, Director of Lab Operations for NGS Services
Latest advancements of melt based 3D printing technologies for oral drug deli...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3A2WcH4
The application of polymer excipients in 3D printing manufacturing is usually limited due to the concerns of filament strength, high processing temperature and large scale manufacturing.
Latest technology developments are targeting a direct melt deposition to simplify the process and enable a constant and efficient process. Two different processing approaches will be presented:
The advanced melt drop deposition, where individual three dimensional geometries can be created by depostition of polymer droplets and the MED® 3D printing technology which allows by precise layer-by-layer deposition to produce objects with well-designed geometric structures.
In this webinar, you will learn:
• Latest advancements of melt based 3D printing approaches
• Application examples for the individual technologies
• Deep dive in the MED® 3D printing technology to design dedicated drug release profiles
Presented by:
Dr. Thomas Kipping, Head of Drug Carriers
Dr. Xianghao Zuo, Deputy Director of R&D, Triastek
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3NDNIKe
Automated, fit-for-purpose tools are essential in CAR-T processing to support sustainable manufacturing of clinical and market-approved cell therapy products. This webinar will discuss how the ekko™ Acoustic Cell Processing System uses acoustic technology as a touchless approach to manipulate cells, enabling a modular tool across the CAR-T manufacturing workflow. Typical performance of templated ekko™ System processes for DMSO washout of leukapheresis material, low volume and high cell concentrate for electroporation preparation, and harvest of expanded T cells will be reviewed.
This webinar will also give an early glimpse at the ekko™ Select System for unmatched T cell selection.
In this webinar, you will:
• Uncover how the ekko™ System supports the broad industrialization of cell therapy, with particular focus on how to achieve low volume, high concentrate cell product for critical transduction and transfection steps
• Discover how ekko™ System for wash and concentrate processes throughout the cell therapy workflow achieve high cell recovery, viability, and effective residual removal
• Preview to ekko™ Select, our cell therapy selection platform, to achieve unmatched ease-of-use with direct processing from leukopaks reducing the need for preparation steps
Presented by:
Benjamin Ross-Johnsrud, Acoustic Technology Expert
Robert Scott, Mechanical Engineer III
Viral safety of biologics: What's changing with the ICH Q5A revision?Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3t7X9tg
How does the ICH Q5A revision impact viral safety strategies for biologics?
Biologics continue to grow at a fast pace. Manufactured using cell lines of human or animal origin, these are at risk of viral contamination making safety strategies critical. A comprehensive risk mitigation strategy using multiple orthogonal measures is a regulatory expectation. ICH Q5A, the globally-harmonized guideline outlines the expectations. ICH Q5A is currently being revised to address recent scientific advancements including novel therapeutic modalities, new manufacturing paradigms, updates in viral clearance applications, and alternate detection technologies. We’ll discuss the expected changes and potential impact on viral safety strategies with case studies and examples.
In this webinar, you will learn about:
• The Importance of virus testing in biologics products
• Regulatory landscape, expectations for the Q5A revision
• What's new and changing
• Examples of alternate testing schedules, impact on viral clearance
Presented by:
Manjula Aysola, Senior Regulatory Consultant
Alison Armstrong, PhD, Sr. Director, Technical and Scientific Solutions
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3adaxWh
When implementing new automation systems, organizations must consider things like deployment time, user adoption, and costs.
They must also consider the cost of doing nothing – that is, what competitive advantage is lost in standing still? What time and quality is lost in repetitive, manual tasks rather than an automated, digital workflow? What operational efficiencies are lost?
In this webinar we examine how a product, process, and system agnostic automation platform can be deployed faster than traditional system specific software while bringing greater operational efficiencies (in many cases over 30% improvement).
To remain competitive in the market, biopharma manufacturers must adopt automation and digital technologies, but most plants still have island of automation consisting of independently functioning, standalone unit operations. This results in operational inefficiency, regulatory concerns, and a poor understanding of the process and product life cycle.
Taking the first, right step must include considering risks, costs, timelines, and technology alternatives. Traditional automation approaches tied to specific systems, processes, and products are, by their nature, limited; while an agnostic platform will address current biomanufacturing business challenges and ensure future readiness. With the right platform, a phased automation implementation can yield operational efficiency gains of up to 30% and improved product quality and regulatory compliance.
In this webinar, let's explore:
• Challenges of automation and digital technology adoption
• What a product, process, and system agnostic platform entails
• Applications and benefits of a process orchestration platform
• Ensuring future readiness with process orchestration
Presented by:
Braj Nandan Thakur, Global Product Manager - Automation
Insights from a Global Collaboration Accelerating Vaccine Development with an...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3Nbb5ug
Get insights and best practices from a multinational team establishing a platform for vaccine production. See how a long-term collaboration on a bench-scale process used to produce a Virus Like Particle (VLP) vaccine for SARS-CoV-2 was successfully converted to a robust GMP-compatible, scalable process.
The COVID-19 pandemic further emphasized the need for collaboration in the development of urgently needed vaccines and therapeutics. In this webinar, we take you behind the scenes of our collaboration with Technovax and Innovative Biotech in which a scalable VLP vaccine platform was optimized for use in a production facility in Nigeria in response to the need for local production of SARS-CoV-2 vaccines. The flexibility and robustness of the platform will enable its rapid deployment to support the West African pandemic readiness program. Initial development of the VLP process began in late 2019 and by March 2020, was already adapted for production of a SARS-CoV-2 vaccine.
In this webinar, you will learn:
• About building a priceless collaborative network with integrated solutions
• Virus-Like Particle Vaccines
• Process Development Overview and Challenges
• Pre-clinical Results and Next Steps
Presented by:
Jose M. Galarza, PhD,
President and Founder of TechnoVax
Naomi Baer,
Business development consultant, Emerging Biotech, BioProcess division
Youssef Gaabouri, Eng. ,
Associate Director, Head of Sales Middle East & Africa, BioProcess division
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3vQf0qv
In the single-use bioprocess industry, X-ray irradiation warrants consideration as an alternate sterilization technology. Using a risk-based qualification testing strategy is important when evaluating and implementing equivalent ionizing irradiation sterilization methods.
The urgent need for life-saving therapies as a result of the global pandemic has reinforced the criticality of flexibility in pharmaceutical manufacturing, including sterilization. The single-use bioprocess industry traditionally has employed gamma irradiation sterilization. X-ray irradiation is being considered as an additional sterilization technology for business and supply continuity. We will share a risk-based qualification testing strategy including Extractables and data generated to support comparability of gamma irradiation and X-ray irradiation as equivalent ionizing irradiation sterilization methods.
In this webinar, you will learn about:
• The comparison of gamma and X-ray irradiation sterilization
• A risk-based qualification test strategy
• Data evaluation of gamma versus X-ray sterilized single-use components
Presented by:
Monica Cardona,
Global Senior Program Manager
Paul Killian, Ph.D.,
R&D Director, Analytical Technologies
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3MJ4u9V
Testing for presence of replication competent adenovirus (RCA) is a key component to ensure patient safety and a requirement for all biologicals manufactured using adenoviral vectors. For many adenoviral-based products, the RCA assay is a rate-limiting assay for lot release.
Join this webinar to learn about a rapid RCA detection assay currently in development, which combines a 7-day culture assay with a highly sensitive molecular endpoint specific for RCA. The method can detect presence of as little as 1 RCA in adenoviral vector material at an approximate concentration of 5x107 - 2x108 vector particles (VP)/mL, making it a suitable method to meet regulatory requirements while accelerating your lot release timelines.
In this webinar, you will learn about:
• Regulatory framework for adenoviral vector products
• Considerations for lot release testing of adenoviral-based therapies
• Advantages of a rapid method for RCA testing on production lot material
Presented by:
Axel Fun, Ph.D.,
Principal Scientist
Alberto Santana, MBA,
Product Manager, Biologics Biosafety Testing
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3vQyN7K
Bitter medicines are an important issue, especially for pediatric applications. As several APIs have bitter tasting components, high intensity sweeteners for taste optimization are of great interest. Join our webinar to discover our new sweetener toolbox enabling safe and stable formulations.
Mask bitter aftertaste for a sweeter pill to swallow! Patients’ compliance and the therapeutic benefit are supported by a pleasant taste of pharmaceutical formulations. With the high intensity sweeteners Neotame and Sucralose, you have efficient tools at hand which are superior to other sweeteners in many aspects:
• excellent sugar-like taste profile
• outstanding sweetness factors
• use effectiveness
• enhanced stability
We will present our new toolbox of two high performance sweeteners and focus on aspects of stability, safety, the application in various dosage forms, and market perception.
In this webinar, you will learn:
• How to optimize the patients' taste experience of your pharmaceuticals
• How sweeteners can be differentiated by their sensory profiles and features
• How our new product offering Neotame can be effectively used in your targeted formulations
Presented by:
Almut von der Brelie,
Senior Manager Strategic Marketing
Excipients for Solid Applications
The Developability Classification System (DCS): Enabling an Optimized Approac...Merck Life Sciences
This whitepaper by Dr. Daniel Joseph Price outlines how poorly soluble drug formulations can be designed using the developability classification system (DCS).
The DCS identifies the root cause of low solubility and enables lean, cost-effective and effective formulations to be developed.
#solubility #pharmaceuticalmanufacturing #oralsoliddosage #drugdevelopment
In this webinar, you will learn about:
The advantages of using advanced intermediates to develop ADC therapies
How to increase ADC solubility and efficiency
Fast, small-scale ADC library generation
Seamless supply chain with reduced complexity and regulatory support
The ADCore product line offers versatile intermediates that simplify the synthesis of common ADC payloads (dolastatins, maytansinoids, and PBDs) by greatly reducing the number of synthetic steps. This translates to savings in development and manufacturing costs and shorter timelines to the clinic. To address the poor solubility of many ADC payloads, ChetoSensar™ was developed to significantly increase the hydrophilicity of the drug linker, which has been shown to also substantially increase the efficacy of ADCs and broaden the therapeutic window.
Lastly, the ADC Express™ service leverages conjugation chemistry and analytical expertise to help design and quickly synthesize sets of potential ADC therapies suitable for screening to simplify candidate selection and get ADC therapies to market faster.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Process equipment characterization – how standardized extractables data support E&L risk assessment
1. Merck KGaA
Darmstadt, Germany
Simone Biel, Regulatory Expert Bioprocessing
Irene Cecchini, Principal Scientist
Webinar September 17th 2020
How standardized extractables data support E&L risk
assessment
Process
Equipment
Characterization
2. 2
The life science business and healthcare
business of Merck KGaA, Darmstadt, Germany
operate as MilliporeSigma and EMD Serono,
respectively, in the U.S. and Canada.
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
3. 1. Risk assessment: regulatory expectations and upcoming USP <665>
2. End-user’s process materials risk management
3. Case studies: extractables data evaluations
4. SUS supplier testing strategy
Agenda
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 20203
4. 4
“The parts of the
production equipment
that come into contact
with the product must
not be reactive,
additive or absorptive
to such an extent that it
will affect the quality of
the product and thus
present any hazard.”
European Commission, EUDRALEX
Volume 4, “Good Manufacturing
Practices, Medicinal Products for
Human and Veterinary Use”
Manufacturing system can affect patient outcome
Good Manufacturing Practices – GMP
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
5. James Oliver, 3D risk assessment model, JVT, Autumn 2008, page 70-76.
55
There are no purification steps in cell and gene
therapy manufacturing processes
Highest risk for patient safety is towards the end of the process
Risk Evaluation
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
6. Understand the nature and amount of potential leachables out of SUS
Regulatory Expectations
6
Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be
provided in the regulatory submission
EMA/CHMP/BWP/187338/2014
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
6.1.3. General issues related to single use equipment
When single use equipment is used in evaluation studies, consideration should be given to leachables
and extractables. Information should be provided on the nature and amount of potential leachables,
and the removal of such impurities. Besides data, this normally includes a risk assessment. Data do
not necessarily need to be generated under actual process conditions, for example supplier data or
data generated under representative model conditions may be suitable. During process evaluation,
small scale studies are acceptable to assess leachable profiles, leachable removal and the impact of
such impurities on cell culture performance. For verification studies, commercial scale equipment
should be used. Various batches of disposable components should be used, as appropriate, in the
manufacturing of verification batches in order to assess their impact on the product quality.
7. BioPhorum and USP <665> are driving the discussion
Representative Model Solvents
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 20207
Potential Leachables or Process
specific Extractables
• Only RELEVANT worst-case scenario
Extractables
• Technology/polymer specific
• ALL worst case conditions according to BPOG/USP<665>
Leachables
• Real Drug & Process
1
2
3
8. 8
Standardized Approach to Extractables Testing – USP <665> draft
“Ensure that the manufacturing system is suitable for its intended use”
“Plastic Components and Systems Used to Manufacture
Pharmaceutical Drug Products and Biopharmaceutical Drug
Substances and Products”
Pharmacopeial Forum PF 46(5), 1st September 2020
Assessment process in two steps to establish the level of
characterization
Initial Assessment
Risk Assessment
Standard extraction protocol
New informational chapter USP <1665> provides additional
information
New General Chapter USP <665>
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
ICH Q3E:
Proposal of a new guideline
for E&L assessment
Concept paper and business
plan published in June 2020
To close a current lack of
alignment, consensus and
clarity among existing
guidelines
9. All manufactured drug products (DP), including
pharmaceuticals (“small molecule” products) and
biopharmaceuticals (biologics)
Drug substances (DS) for biologics
Single-use (SU) and Multi-use (MU) systems
Plastic components used in the manufacturing of
pharmaceutical and/or biopharmaceutical drugs
include, but are not necessarily limited to, bags, bioreactors,
cassettes, chromatographic columns, connectors, filling
needles, filters, sensors, stir bars, tubing, valves, and
vessels.
Diaphragms, gaskets, and O-rings constructed of a polymer
USP <665>
Scope
9
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
processes that involve liquids
10. Active pharmaceutical ingredients (APIs) that are the
precursors to nonbiologic and non-biopharmaceutical DPs
well-characterized, highly purified substances
Auxiliary items for dispensing / transferring of ingredients
Plastic spoons, funnels, pipettes, graduates cylinders,
beakers, …
Relative short contact time
Diaphragms, gaskets, and O-rings constructed of elastomeric
materials (natural rubbers)
no plastic materials
USP <665>
Out of Scope
10
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
11. First step: component or system testing needed?
Initial Assessment
Is the component isolated from the process
stream?
Component is in scope
Can a comparator component or system be
established?
Component is out of scope.
No component testing is required.
Proceed to risk assessment
Assessment is complete.
No component testing is required.
no
yes
yes
yes
no
11
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
Is the component in contact with a liquid
process stream?
Component is out of scope.
No component testing is required
no
12. 12
Second step: the likelihood of leaching
Risk Assessment
Four Risk Dimensions per USP <1665>
1. The chemical composition of the process stream
2. The nature of the component's materials of construction
3. The temperature of contact
4. The duration of contact
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
And the likelihood to persist
- Accumulation or elimination of process-equipment related leachables (PERL)
- dosage form, daily dose volume, therapy duration
13. Organic
solvents (by
volume)
Surfactants
(by weight)
Blood/blood
-derived
substances
(by weight)
Lipids and
proteins (by
weight)
pH
Aqueous
Level 1
<5% <0.1% <1% <1% ≥ 3 and ≤ 9
Somewhat
organic
Level 2
5-40% 0.1-0.5% 1-25% 1-5%
Highly organic
Level 3
>40% >0.5% >25% >5% <3 or >9
Risk Dimensions per USP <1665>
Process Stream
If the process streams contain multiple solubilizers, e.g. protein and surfactant, the risk increases
Process
Stream
13
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
14. Risk Dimensions per USP <1665>
Material of Construction, Temperature and Duration
Additives
(by weight)
Treatment
for
sterilization
Processing
Inert
Level 1
<0.1%
Intermediate
Level 2
0.1-1%
chemical
adhesives/bo
nding of
component's
materials
Reactive
Level 3
>1%
Irradiation
/chemical
treatment
chemical
adhesives/bo
nding of
component's
materials
Temperature
(°C)
Duration
Level 1 Frozen (<-10) < 24 hrs
Level 2
refrigerated
(2-8)
Ambient (15-
25)
1-7 days
Level 3
Elevated
(>30)
> 7 days
DurationMaterial Tempera-
ture
14 Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
Clearance and clinical mitigating factors should be taken into account when establishing the
characterization level
Flushing can be used to reduce the material reactivity terms by one level
15. 15
Risk Evaluation Matrix
Risk Score to Risk Level
Dimension Scores of
Level 3
Score Risk Level Remark
Four 3333 C (high risk)
Three 3332 C
3331 C
Two 3322 C
3321
B (medium risk) or
C
if Level 2 is in temperature, solvent, or
duration dimesions, then C, otherwise B
3311
A (low risk)
or B
if one of the Level 1 scores is in the
component dimension, A, otherwise B
One 3222 B
3221 B
3211 B or A
if one of the Level 1 scores is in the
component dimension, A, otherwise B
3111 A
No 2222 B
XXXX A All other combinations
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
Link the Risk Sequence
with a Level of risk
characterization
Use mitigation factors to
adjust the result
(by -1 or -2)
16. Downstream Components Require Higher Level of Testing
Final Sterilization
Risk
Dimension
Material Tempe-
rature
Duration Process
Stream
Risk Score Risk
Level
Mitigating
Factor
Final Risk
Level
Final
Sterilization
Reactive
(3)
Ambient
(2)
1-7 days
(2)
Highly
Organic
(3)
3223 C 0 C
16 Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
A component used later
in the process presents a
higher risk to the patient
Few or no opportunities
for clearance of any
leachables
Mitigation factor depends
on the process
17. Risk
Level
Extraction Solution Component Testing
Low 50% Ethanol
Non-volatile residue
UV absorbance
Medium 50% Ethanol
Organic extractables
profiling
High
1. 50% EtOH
2. 0.2M KCl, HCl, pH 3
3. 0.1M Phosphate buffer,
pH 10
Organic extractables
profiling
Extractable elements
(as necessary and
appropriate)
USP <665>
Testing Requirements
17
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
Accelerated extraction at
40°C
Extraction duration depends on
individual component and its
typical manufacturing
operations
1, 7, or 21 days
Dynamic extraction
Surface-area-to-solution
volume ratio of 6 cm2/ml
18. 1. Risk assessment: regulatory expectations and upcoming USP <665>
2. End-user’s process materials risk management
3. Case studies: extractables data evaluations
4. SUS supplier testing strategy
Agenda
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 202018
19. Healthcare’s pharma & biotech manufacturing network
CMO network
Rio
Mexico City
Montevideo
Atsugi
Mollet
Darmstadt
Nantong
Semoy
Aubonne
Vevey
Tres Cantos
Bari
Martillac
Guidonia
Ivrea
17 sites in 10
countries produce
our biotech and
pharmaceutical
medicines for the
more than 72 million
patients across the
globe
Calais
Meyzieu
Guidonia Site main
Activities
Analytical & Pharmaeutical Development
Biotech
Biotech Centralized QC & Stability Center
Global Analytical- Pharmaceutical Science &
Innovation
Chemical & Pharmaceutical Dev. NCEs
19 Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
21. ICH Q9: Higher risk requires
higher level of qualification
• The evaluation of the risk to quality should
be based on scientific knowledge and
ultimately link to the protection of the
patient
• The level of effort, formality and
documentation of the quality risk
management process should be
commensurate with the level of risk
21
Process materials risk management
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
22. 22
Process materials risk management
Risk Mitigation/
Risk Control
Risk Assessment
Process
Mapping
and
process
conditions
Materials
list
FMECA risk
analysis
Critical
Material
Attributes
Preliminary
Process
Control
Strategy
Action List
Review of
risk and
Process
Control
strategy
E&L risk
analysis
Studies to
be planned
if necessary
Risk
Review
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
Risk
Review
Analysis
Strategy
plan
process
evaluation
Control
assessment
23. 23
Extractables and Leachables assessment
Risk based approach
decision tree
Pre-work
Extraction
Leachables
Safety
assessment
output RISK
score
output RISK
Mitigation/
Risk Control
output Safety
assessment &
Risk acceptance
23
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
24. 24
Extractables and Leachables assessment
Risk based approach – risk assessment template
BPOG proposed RA template
The risk assessment is supported in the BioPhorum Operations Group (BPOG)
«Best pactice guide for evaluation leachables risk from polymeric
single-use systems used in biopharmaceutical manufacturing»
F&F operations
considered at
greater risk for
impurities vs
USP/DSP
operations.
This factor
therefore has a
higher weight in
the risk
assessment.
The conditions of use
make the difference for
the final score!
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
25. 25
Extractables and Leachables assessment
Risk based approach – risk assessment template
Adapted Risk Assessment template
Companies build up their own internal template to meet specific needs and procedures.
Medium
Risk
High
Risk
Low
Risk
Material meets compendial requirements
(e.g. USP, Class VI, EP…)
Low risk requirements plus appropriate Extractables
data evaluation that brackets the intended use available.
TOC/NVR data minimum test requirement to be used for
risk mitigation, should be complemented with FTIR info
for extractables identification to be submitted to
toxicological assessment.
Medium-risk requirements plus more complete
Extractables data involving different extraction
solvents/solutions and conditions and a variety of
techniques such as:
- GC-MS; LC-DAD; LC-MS; FTIR; NMR for organic
species identification and quantification.
- ICP/MS, ICP-OES, AAS for elemental analysis.
Leachables/Simulation studies may be needed.
Risk Classification & Requirements
25 Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
26. 26
Extractables and Leachables assessment
Risk based approach – risk scoring example
Materials list and
dimensions:
Tube type 1
Tube type 2
Tube type 3
Tube type 4
Connector 1
Connector 2
Connector 3
Filter
SU mix Bag
Higher contact time
here during the DS
transferring and mixing
step (up to 72h) in the
bag.
Lower contact time from
this point on (<24h)
Very low surface-to
volume ratio for
connectors
Highest
risk score
here
Medium
risk
score
here
26 Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
27. 27
Extractables and Leachables assessment
Risk based approach – risk mitigation
Use of the extractables data for potential exposure evaluation
Analytical
Data
Potential level
into the DP
Max daily
Dose
Potential
Patient
Exposure
Exposure
< TTC?
(e.g. 1,5
µg/day)
Yes
No further
action
No
Check
Specific
Compound
PDE
(if known)
Exposure
< PDE?
Yes
No further
action
No
Plan Adequate
Simulation/
Leachable
Study
𝐄𝐱𝐩𝐨𝐬𝐮𝐫𝐞 µ𝐠/𝒅𝒂𝒚 =
𝐄𝐱𝐭𝐫𝐚𝐜𝐭𝐚𝐛𝐥𝐞𝐬 𝐥𝐞𝐯𝐞𝐥 𝐩𝐞𝐫 𝐜𝐨𝐧𝐭𝐚𝐜𝐭 𝐬𝐮𝐫𝐟𝐚𝐜𝐞
𝒎𝒈
𝒄𝒎 𝟐 ∗ 𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐒𝐮𝐫𝐟𝐚𝐜𝐞 𝒄𝒎 𝟐
𝐏𝐫𝐨𝐜𝐞𝐬𝐬 𝐒𝐭𝐫𝐞𝐚𝐦 𝐕𝐨𝐥𝐮𝐦𝐞 𝑳
∗ 𝑫𝑷 𝒎𝒂𝒙 𝒅𝒂𝒊𝒍𝒚 𝒅𝒐𝒔𝒆 (𝒎𝑳/𝒅𝒂𝒚)
Exposure
< PDE?
Yes
Exposure
< 30%
PDE?
Yes
No further
action
No
Plan adequate
Simulation/
Leachables study to
control EI in the DP
Evaluation for Elemental Impurities:
Evaluation for Organic Impurities:
27 Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
TTC can be established based on posology and
relative toxicity.
30% PDE concept as threshold limit
established in the ICH Q3D for elemental
impurities can also be applied to organics
28. 28
Extractables and Leachables Assessment
Process materials risk management
Process mapping
1
List of SU materials, available info and
conditions of use
Family Process step
Component
name/
Supplier
Material of
construction
Certifications
Surface –
to-volume
ratio
Max.
Product
Contact
Duration
Temper
ature
Compounding
bag
DS pooling and
mixing
SU mix Bag Pall
Film: Inner layer Ultra
Low Density
Polyethylene
Gas barrier layer EVOH
Outer layer Ultra Low
Density Polyethylene
Ports Polyethylene
USP Class VI
USP 87 (cytotoxicity)
ISO 10993 (biological
compatibility)
USP 661
Ph.Eur. (Section 3.1.5); JP
(Section 61 Part 1);
European directive
85/572/EEC
0,02 m^2/L 34h
Room
Temp
Connectors and
fittings
DS pooling and
mixing
MPC connectors
Sartorius
Polycarbonate; Silicone
USP class VI <0.001
m^2/L
2-10
Room
Temp
DP transfer
KPC Pall
connectors
Polycarbonate
USP class VI <0.001
m^2/L
18h
Room
Temp
Filters
DP and
excipients
filtration
Millipak 200 filter
Filter membrane PVDF
Structural components
Polycarbonate
USP <88>,
USP class VI
0,03 m^2/L 3h
Room
Temp
DP filtration
Opticap XL5
Filter
Filter membrane
PVDF
Structural
components
polypropylene
USP <88>,
USP class VI 0,01 m^2/L 3h
Room
Temp
Tubing
DP transfer tubes Raumedic
Platinum-cured silicone
(SIK8694)
USP class VI
ISO 10993-5
0,02 m^2/L 18h
Room
Temp
DS/DP transfer
PumpSil tube,
Watson Marlow
Platinum-cured silicone
USP Class VI
ISO 10993-4, 5, 6, 10, 11
EP 3.1.9
0,01 m^2/L 2-10 h
Room
Temp
Final fill
Peristaltic pump
tube, B+S
Platinum-cured silicone
FDA 21 CFR 177.2600, EP
3.1.9, USP Class VI, ISO
10993 (10&11), NSF-51
<0.001
m^2/L
18h
Room
Temp
Exemplified list
Process
Mapping
and
process
conditions
Materials
list
FMECA risk
analysis
Critical
Material
Attributes
Preliminary
Process
Control
Strategy
Action List
Review of
risk and
Process
Control
strategy
E&L risk
analysis
Studies to
be
planned if
necessary
2
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
29. 4
29
Extractables and Leachables Assessment
Process materials risk management
Process
Mapping
and
process
conditions
Materials
list
FMECA risk
analysis
Critical
Material
Attributes
Preliminary
Process
Control
Strategy
Action List
Review of
risk and
Process
Control
strategy
E&L risk
analysis
Studies to
be
planned if
necessary
DS thawing/
Transfer
Compounding
and Mixing
Step
Filtration Step Final Filling
PumpSil tube
(Watson
Marlow)
Pall mix bag
Raumedic
Tubes
Filters
Connectors
and
adaptors
Peristaltic
pump tubes
Consideration Scoring
Distance along
production
stream (DAS)
9 9 9 9 9 9
Exposure
Temperature (ET)
5 3 5 5 5 5
Exposure
duration (ED)
3 5 3 3 3 3
Process Fluid
Interaction (PFI)
3 3 3 3 3 3
Dilution ratio (DR) 3 5 3 3 1 1
Material
sterilization pre-
treatment (MS)
9 9 9 5 9 5
Total score
(LRR)
high high high medium medium medium
E&L Risk scoring
Product Contact Item
Material use in
manufacturing process
Risk Level Risk Mitigated
Pall Allegro Mixing Bag Compounding Step High Risk Yes
Raumedic platinum cured silicone
tubing
Solution Transferring High Risk Yes
Watson Marlow PUMPSIL tubing Solution Transferring High Risk Yes
PC Connectors Tubing Connectors Medium Risk Yes
Durapore® 0.22 μm
Hydrophilic Millipak® Filter Device
(MPGL20)
Filter for formulated solution Medium Risk Yes
Durapore® 0.22 μm
Hydrophilic Opticap® XL Capsule
Filter for formulated solution Medium Risk Yes
B+S peristaltic pump Pt cured silicone
tubes
Peristaltic pump tubes, used in
the filling step
Medium Risk Yes
E&L Risk mitigation
Extractables
data evaluation
with exposure
calculation &
safety
assessment
3
Control Strategy
Risk associated to each material is finally revised after
extractables data evaluation and toxicological assessment
Control strategy identifies actions to
do to mitigate and control the risk.
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
30. 1. Risk assessment: regulatory expectations and upcoming USP <665>
2. End-user’s process materials risk management
3. Case studies: extractables data evaluations
4. SUS supplier testing strategy
Agenda
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 202030
31. 31
Extractables and Leachables assessment
Risk mitigation: Case Study 1
Extractables data from Supplier were clear and complete:
- Extraction conditions clear and well documented
- Complete analytical panel applied (GC/MS, LC/MS, ICP/MS, NVR) and comprehensive data format
- Comparison with the previous material was done
Case Study: Supplier Notification of material change in F&F process – impact evaluation
Supplier change of small polyethylene injection ports installed on polyethylene mixing bag used for the
pooling/compounding step.
Medium
Risk
Organic Extractables list (mg) from Supplier
material characterization report
Surface
submitted to
extraction
(cm^2)
Total
extractables
mg/cm^2
Total surface
normally in
contact with the
product Cm^2
Minimum DP
batch
volume (L)
Total
extractables
conc in DP
(worst case) -
mg/L
DP max
daily dose
(mL)
Max
Leachables
exposure
(µg/day)
Is exposure
<1,5
µg/day?
(yes/no)
Hexane 1.33 554 0.02 70 12 0.105 3.2 0.34 yes
2,4 di tert butylphenol 0.25
1,3 bis (1,1-dimethylethyl) benzene 1.12
Irgafos 168 Ox 0.1
Hexadecanoic acid 3.22
Octadecanoic acid 2.94
Erucamide 0.02
Other (NVR) 1
total 10.01
Elemental Impurities (µg)
Max Leachables
exposure
(µg/day)
Is exposure <
PDE? (yes/no)Element
ICH Q3D
Class
Parenteral PDE
(µg/day)
Detected level
(µg)
Copper Cu 3 300 3 0.000101 yes
Lithium Li 3 250 0.1 0.000003 yes
Outcome:
Potential exposure judged negligible: no relevant impact on the product safety.
Risk accepted change implemented
Generic TTC
applied here
31
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
32. 32
Extractables and Leachables assessment
Risk mitigation: Case Study 2 – filter validation
Identified Extractables
compound
CAS n.
Extractables
level
(mg/Filter)
Potential Exposure
(µg/person/day)
PDE
(µg/person/day)
Is exposure
<PDE?
(yes/no)
Poly(acrylate) esters 25037-45-0 87.9 88.1 120 Yes
Irganox 3114 27676-62-6 87.9 88.1 20000 Yes
Tris (2,4-di-tert-
butylphenyl)
phosphate
95906-11-9 87.9 88.1 15000 Yes
Irgafos 168 31570-04-4 87.9 88.1 15000 Yes
Erucamide 112-84-5 87.9 88.1 100000 Yes
Propylene Glycol
Monostearate
1323-39-3 87.9 88.1 600000 Yes
Worst case data from
Extractables report 175 mg for
2 filters.
Based on filters conditions of use potential
leachables concentration in the final DP
and patient exposure has been calculated
No safety risk!
Low dose Product
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
33. 33
Extractables and Leachables assessment
Risk mitigation: Case Study 3 – filter validation
Worst case data correspond to about 183 mg of total
extractables.
Filter validation study extraction study under worst case conditions as per
Customer’s process conditions. Extraction done in static mode by water and ethanol.
NVR and TOC data + RP-HPLC, GC/MS and FTIR for the extractables identification.
The results are used to generate a safety assessment on the filters.
Extractables identified as mainly polyacrylate esters by FTIR
and later confirmed by MS spec.
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
34. 34
Extractables and Leachables assessment
Risk mitigation: Case Study 3 – filter validation
Potential exposure scenario calculation:
Exposure =
𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑎𝑏𝑙𝑒𝑠 𝑤𝑜𝑟𝑠𝑡 𝑐𝑎𝑠𝑒 𝑑𝑎𝑡𝑎
𝐹𝑖𝑙𝑡𝑒𝑟 𝑓𝑙𝑢𝑠ℎ𝑖𝑛𝑔 𝑣𝑜𝑙𝑢𝑚𝑒
x DP max daily dose
Calculated Exposure >TTC for
polyacrylates that is 120
µg/person/day.
Safety Assessment did not pass
Problem: Extractables data showed a potential high level of polyacrylate esters in the product. Based on the filter
use and product dosage the expected level calculated might potentially exceed safety limits for these compounds.
Action Plan:
1) Require for more comprehensive extractables data obtained by LC/DAD/MS
providing extractables ID and semiquantification Confirm the extractables
ID and levels Emprove® Dossier!
2) Perform a Flushing study to determine the correct flush volume necessary
to reduce the potential leachables to acceptable levels.
3) Verify the leachables presence into the final DP
High dose Product
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
Don’t panic
35. 35
Extractables and Leachables assessment
Risk mitigation: Case Study 3 – filter validation
Action 1:
LC/DAD/MS Emprove® Data (from Supplier) confirmed extractables ID.
The actual levels detected by LC/DAD/MS were much lower than the TOC or NVR data.
Nevertheless the potential exposure is still high risk still not mitigated by theory.
Action 2:
Ad hoc flushing studies in collaboration with the supplier. Representative conditions applied.
Filter flushing with water under dynamic mode. Sampling at different timepoints.
TOC to evaluate the level of leachables.
12 Liters filter flushing guarantees the TOC to minimum level.
12 Liters
Risk Mitigated
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
36. 36
Action 3:
Ad hoc leachables testing to verify the level of polyacrylates in the DP.
Dedicated liquid MS analysis was set up using calibration curve using Poly
hydroxypropyl acylate (PHPA) mixture as reference material.
The testing showed that the polyacrylates were below analytical threshold.
MS spectrum of Reference PHPA at 50 ppm:
Polyacrylates < 1 µg/mL (AET)
Safety guaranteed.
Extractables and Leachables assessment
Risk mitigation: Case Study 3 – filter validation
Risk Mitigated
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
37. Process Equipment Characterization with Standardized Extractables Data | 17 Sept 202037
Extractables and Leachables assessment
Regulatory request
Question received from health authority :
“A list of single-use product contact materials used in
the manufacturing of [xxx omitted…] is presented […]
Provide a detailed summary of the results of the
extractables/leachables studies and the exposure
safety assessment used to support their use”.
We prepared a response with all the requested
additional data already previously collected.
The Response was well
received and accepted!
38. 38
Main points for
improvement:
• Collaboration and data sharing
• Not easy to find comprehensive
Extractables data for all the
materials especially complicated
for Tubing or small parts. Format
sometimes not easy for further data
interpretation.
• Standard data are mostly based on
basic analyses as TOC and NVR;
characterization data needed for tox
evaluation; at least FTIR
identification of extractables
• Standardized protocols and
quantitative data are more than
welcomed
Positive aspects:
• Risk assessment approach
efficiently manages the risk associated
to SU material
• RA template is a powerful tool for
manufacturing sites to collect and
elaborate the information received
from suppliers and to prepare
adequate data package to justify the
use of SU materials
• Use in dossier drafting and responses
to Health Authorities
• Good interaction with Suppliers for
getting comprehensive data and for
support in case specific studies are
necessary
Overall Summary and
Considerations
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
39. 1. Risk assessment: regulatory expectations and upcoming USP <665>
2. End-user’s process materials risk management
3. Case studies: extractables data evaluations
4. SUS supplier testing strategy
Agenda
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 202039
40. Revised BioPhorum protocol published in April 2020
Extractables Best Practices Guide
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 20204040
• Updated Extractables Protocol
• New reference guide for Quality expectations
from a testing laboratory
• New guide for reporting extractables test data
• Website has a new dedicated extractables portal
linking to suppliers websites
https://www.biophorum.com/resource/extractables-
and-leachables/extractables-portal/
41. Emprove® Extractables Test Strategy
BPOG Requirements USP <665> draft Emprove® Program Approach
Scope Single-use components in contact with
fluid path (for biopharmaceutical
manufacturing)
Single-use and multi-use components
and devices with fluid path contact (for
pharmaceutical and biopharmaceutical
manufacturing)
Single-use and multi-use components
and devices with fluid path contact, all
relevant existing and new products
Solvents
1) 50% Ethanol
2) 1% Polysorbate 80
3) 5M NaCl
4) 0.5N NaOH
5) 0.1M Phosphoric Acid
6) WFI
1) 50% Ethanol
2) 0.2M KCl, pH 3
3) 0.1M Phosphate buffer, pH 10
= BPOG + USP <665>
Analytical methods
HPLC-DAD/MS (APCI,ESI, +/-)
ICP/MS DI-GC/MS, HS-GC/MS
TOC pH
NVR
Described in USP <1663>. Broader
scope in methods selection.
= BPOG
Additionally: IC and Conductivity
Time points 1-3, dependent on component 1, dependent on component = BPOG + USP <665>
Pre-treatment
…‘should be pre-treated the same way
before … extractables testing…‘
“…tested when they have been
conditioned or processed in a manner
consistent with their intended use and
as specified in the manufacturer's
instructions for use.”
• Separate tests and reports for gamma
irradiation or autoclave pre-treatment
• No pre-flush unless required (worst
case)
Timing Published 2014, updated 2020 3rd draft published September 2020
• Reports released since August 2017 for
many key Filtration and Single Use
Products.
41 Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
42. Components to Validate
42 Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
43. 43
…and it becomes even fuzzier when looking closer
Our components
3rd Party components
E.g. Tubing, connectors, fittings
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
44. Process Equipment Characterization with
Standardized Extractables Data | 17 Sept 202044
Report for Mobius® SU
library components:
Extractables Data as per
BPOG and USP <665>
Are available off-the-
shelf
presents full extractables
profile for the list of
library components from
specific component family
Emprove® Extractables report for Mobius® Single Use Library Components
45. 45
There is more to do than collecting the data
Prerequisite to Patient Safety Evaluation
Maximise efforts towards
assuring patient safety
Process Equipment Characterization with Standardized Extractables Data | 17 Sept 2020
46. Process Equipment Characterization with Standardized Extractables Data | 17 Sept 202046
Adoption of SUS in manufacturing processes
Regulatory expectations to understand the nature and
amount of potential leachables.
Risk evaluation by the drug manufacturer
USP <665> provides guidance of risk assessment and
testing approach for SUS.
USP <1665> helps to establish the level of component
chemical characterization.
Standardized extractables data package
SUS suppliers provide comprehensive packages to
enable initial qualification and to assure material safety.
All about patient safety!